A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection.
OBJECTIVE
Hepatitis B viral markers may be useful for predicting outcomes such as liver-related deaths or development of hepatocellular carcinoma. We determined the frequency of these markers in different clinical stages of chronic hepatitis B infection.


METHODS
We compared baseline hepatitis B viral markers in 317 patients who were enrolled in a prospective study and identified the frequency of these tests in immune-tolerant (IT) patients, in inactive carriers, and in patients with either hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis or cirrhosis.


RESULTS
IT patients were youngest (median age 27 years) and HBeAg-negative patients with cirrhosis were oldest (median age 58 years) (p = 0.03 to <0.0001). The male to female ratio was similar both in IT patients and in inactive carriers, but there was a male preponderance both in patients with chronic hepatitis and in patients with cirrhosis (p < 0.0001). The A1896 precore mutants were most prevalent in inactive carriers (36.4%) and HBeAg-negative patients with chronic hepatitis (38.8%; p < 0.0001), and the T1762/A1764 basal core promoter mutants were most often detected in HBeAg-negative patients with cirrhosis (65.1%; p = 0.02). Genotype A was detected only in 5.3% of IT patients, and genotype B was least often detected in both HBeAg-Positive patients with chronic hepatitis and cirrhosis (p = 0.03). The hepatitis B viral DNA levels were lowest in inactive carriers (2.69 log(10) IU/mL) and highest in IT patients (6.80 log(10) IU/mL; p = 0.02 to <0.0001). At follow-up, HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for 57 of 64 (89.1%) liver-related deaths (p < 0.0001).


CONCLUSIONS
Differences in baseline hepatitis B viral markers were detected in patients in various clinical stages of hepatitis B virus infection. HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for the majority of the liver-related fatalities.
Tong
Myron John
MJ
Hsu
Leeyen
L
Hsien
Carlos
C
Kao
Jia-Horng
JH
Durazo
Francisco Antonio
FA
Saab
Sammy
S
Blatt
Lawrence Mitchell
LM
J Infect Dis. 2002 Nov 1;186(9):1335-8
12402204
Semin Liver Dis. 2003 Feb;23(1):47-58
12616450
Gastroenterology. 2006 Apr;130(4):1153-68
16618410
J Hepatol. 2002 Sep;37(3):355-63
12175631
J Natl Cancer Inst. 2008 Aug 20;100(16):1134-43
18695135
JAMA. 2006 Jan 4;295(1):65-73
16391218
Hepatology. 2002 Dec;36(6):1408-15
12447866
Hepatology. 2000 May;31(5):1037-44
10796877
Gastroenterology. 2002 Jun;122(7):1756-62
12055581
J Hepatol. 1994 May;20(5):636-40
8071540
Mayo Clin Proc. 2007 Aug;82(8):967-75
17673066
Gastroenterology. 2003 Feb;124(2):327-34
12557138
Hepatology. 2007 Aug;46(2):395-401
17628874
Gastroenterology. 2006 Mar;130(3):678-86
16530509
J Hepatol. 2007 Dec;47(6):760-7
17928090
J Med Virol. 2004 Mar;72(3):363-9
14748059
Gut. 2005 Nov;54(11):1610-4
15871997
Hepatology. 2008 Oct;48(4):1070-8
18688879
Gastroenterology. 2008 May;134(5):1376-84
18471514
J Hepatol. 2008 Feb;48(2):335-52
18096267
Hepatology. 2005 Jul;42(1):121-9
15962291
Lancet. 1989 Sep 9;2(8663):588-91
2570285
Gastroenterology. 2001 Jun;120(7):1828-53
11375963
J Clin Microbiol. 2002 Apr;40(4):1207-9
11923332
J Gastroenterol Hepatol. 2007 Jul;22(7):973-6
17489961
World J Gastroenterol. 2006 Nov 7;12(41):6620-6
17075974
Semin Liver Dis. 2006 May;26(2):130-41
16673291
J Viral Hepat. 2005 Jul;12(4):373-9
15985007
Dig Dis Sci. 2009 Jun;54(6):1337-46
19242792